Search

Your search keyword '"Derosa, Lisa"' showing total 481 results

Search Constraints

Start Over You searched for: Author "Derosa, Lisa" Remove constraint Author: "Derosa, Lisa"
481 results on '"Derosa, Lisa"'

Search Results

1. Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

2. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

4. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

5. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

7. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

8. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

9. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

10. Melanoma and microbiota: Current understanding and future directions

11. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma

12. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

13. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

14. Benzodiazepines compromise the outcome of cancer immunotherapy.

15. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.

16. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

17. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

18. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

19. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease

20. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

21. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

22. Multifaceted modes of action of the anticancer probiotic Enterococcus hirae

24. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

25. State of the art and the future of microbiome-based biomarkers:a multidisciplinary Delphi consensus

27. Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications.

28. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

29. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

30. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study

33. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

37. 1510 Multiomic functional biomarkers for cancer prediction and early detection

38. Longitudinal gut microbiome changes in immune checkpoint blockade in advanced melanoma

39. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

46. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

47. Immunodynamics of explanted human tumors for immuno‐oncology

50. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Catalog

Books, media, physical & digital resources